World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis

  • Manolis N. Saridomichelakis*
  • , Gad Baneth
  • , Silvia Colombo
  • , Filipe Dantas-Torres
  • , Lluís Ferrer
  • , Alessandra Fondati
  • , Guadalupe Miró
  • , Laura Ordeix
  • , Domenico Otranto
  • , Chiara Noli
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Background: Canine leishmaniosis (CanL) due to Leishmania infantum remains common, and veterinarians do not always follow scientifically sound approaches for diagnosis, treatment and prevention. Objectives: To provide consensus guidelines for diagnosis and evidence-based guidelines for treatment and prevention of CanL. Methods and Material: Clinical consensus guidelines for the diagnosis were structured based on literature and authors' experience. Three electronic databases were searched for randomised controlled trials, systematic reviews and meta-analyses on treatment and prevention. Results, Conclusions and Clinical Importance: Diagnosis should be based on compatible clinical signs and/or clinicopathologic abnormalities, exclusion of differentials, demonstration of infection and increased concentration of anti-Leishmania IgG (quantitative serology). Euthanasia for public health purposes is not recommended and drugs with anti-Leishmania activity should be avoided in subclinically infected dogs. Recommended treatments include meglumine antimoniate-allopurinol (first-line treatment), miltefosine-allopurinol (first-line treatment) and aminosidine-allopurinol (second-line treatment); marbofloxacin may be considered in dogs with advanced chronic kidney disease. In endemic areas, recommended measures for prevention include deltamethrin 4% collar, flumethrin 4.5%-imidacloprid 10% collar or permethrin 50%-imidacloprid 10% spot-on, not using infected blood products for transfusion, not breeding seropositive bitches or dogs with CanL, administration of domperidone (seronegative dogs) and dietary nucleotides-active hexose correlated compound (subclinically infected, seropositive dogs). Vaccination with LiESP with MDP may be considered, whereas protein Q vaccine is recommended in areas with very high rates of seroconversion. In non-endemic areas, recommended measures include not using infected blood products for transfusion and removal of infected female dogs from reproduction.

Original languageEnglish
Pages (from-to)723-787
Number of pages65
JournalVeterinary Dermatology
Volume36
Issue number6
DOIs
StatePublished - Dec 2025

Bibliographical note

Publisher Copyright:
© 2025 The Author(s). Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of ESVD and ACVD.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • allopurinol
  • aminosidine
  • deltamethrin
  • domperidone
  • flumethrin
  • meglumine antimoniate
  • miltefosine
  • nutritional supplement
  • permethrin
  • vaccine

Fingerprint

Dive into the research topics of 'World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis'. Together they form a unique fingerprint.

Cite this